Knight Therapeutics Inc. (TSX: GUD)
Canada
· Delayed Price · Currency is CAD
5.64
-0.03 (-0.53%)
Oct 29, 2024, 4:00 PM EDT
Knight Therapeutics Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Revenue | 337.87 | 328.2 | 293.56 | 243.48 | 199.52 | 47.46 | Upgrade
|
Revenue Growth (YoY) | 3.50% | 11.80% | 20.57% | 22.03% | 320.39% | 279.69% | Upgrade
|
Cost of Revenue | 174.44 | 175.55 | 155.5 | 128.07 | 117.83 | 20.54 | Upgrade
|
Gross Profit | 163.43 | 152.65 | 138.06 | 115.41 | 81.69 | 26.92 | Upgrade
|
Selling, General & Admin | 90.48 | 83.69 | 88.62 | 74.38 | 70.74 | 24.23 | Upgrade
|
Research & Development | 19.81 | 17.55 | 14.76 | 12.69 | 11.73 | 3.91 | Upgrade
|
Operating Expenses | 155.43 | 146.28 | 155.12 | 128.24 | 108 | 31.56 | Upgrade
|
Operating Income | 8 | 6.37 | -17.06 | -12.83 | -26.31 | -4.64 | Upgrade
|
Interest Expense | -11.55 | -12.49 | -6.6 | -3.62 | -3.4 | -0.37 | Upgrade
|
Interest & Investment Income | 11.36 | 12.58 | 10.63 | 7.38 | 14.32 | 23.54 | Upgrade
|
Earnings From Equity Investments | - | - | - | - | - | 0.91 | Upgrade
|
Currency Exchange Gain (Loss) | -13.93 | -15.17 | 7.44 | -3.74 | -14.16 | -1.39 | Upgrade
|
Other Non Operating Income (Expenses) | -16.35 | -7.32 | -22.68 | 19.07 | 60.3 | 17.15 | Upgrade
|
EBT Excluding Unusual Items | -22.47 | -16.03 | -28.27 | 6.27 | 30.76 | 35.2 | Upgrade
|
Merger & Restructuring Charges | - | - | - | - | -3.69 | -8.02 | Upgrade
|
Gain (Loss) on Sale of Investments | - | - | - | - | 4.17 | - | Upgrade
|
Gain (Loss) on Sale of Assets | - | - | - | - | 2.95 | - | Upgrade
|
Asset Writedown | -9.26 | -9.26 | -23.98 | - | -0.66 | -4.23 | Upgrade
|
Other Unusual Items | 8.05 | 3.3 | 8.29 | 0.42 | -1.44 | -0.18 | Upgrade
|
Pretax Income | -23.69 | -21.99 | -43.96 | 6.69 | 32.09 | 22.78 | Upgrade
|
Income Tax Expense | -2.46 | -5.15 | -14.07 | -8.99 | 0.33 | 4.75 | Upgrade
|
Earnings From Continuing Operations | -21.23 | -16.84 | -29.89 | 15.68 | 31.76 | 18.03 | Upgrade
|
Minority Interest in Earnings | - | - | - | - | 10.31 | -3.52 | Upgrade
|
Net Income | -21.23 | -16.84 | -29.89 | 15.68 | 42.07 | 14.52 | Upgrade
|
Net Income to Common | -21.23 | -16.84 | -29.89 | 15.68 | 42.07 | 14.52 | Upgrade
|
Net Income Growth | - | - | - | -62.74% | 189.78% | -39.71% | Upgrade
|
Shares Outstanding (Basic) | 103 | 107 | 115 | 124 | 132 | 140 | Upgrade
|
Shares Outstanding (Diluted) | 103 | 107 | 115 | 125 | 132 | 140 | Upgrade
|
Shares Change (YoY) | -7.80% | -6.46% | -7.73% | -5.65% | -5.82% | -2.19% | Upgrade
|
EPS (Basic) | -0.21 | -0.16 | -0.26 | 0.13 | 0.32 | 0.10 | Upgrade
|
EPS (Diluted) | -0.21 | -0.16 | -0.26 | 0.13 | 0.32 | 0.10 | Upgrade
|
EPS Growth | - | - | - | -60.55% | 219.21% | -40.68% | Upgrade
|
Free Cash Flow | 60.64 | 34.99 | 42.12 | 40.79 | -17.58 | 4.49 | Upgrade
|
Free Cash Flow Per Share | 0.59 | 0.33 | 0.37 | 0.33 | -0.13 | 0.03 | Upgrade
|
Gross Margin | 48.37% | 46.51% | 47.03% | 47.40% | 40.94% | 56.72% | Upgrade
|
Operating Margin | 2.37% | 1.94% | -5.81% | -5.27% | -13.19% | -9.77% | Upgrade
|
Profit Margin | -6.28% | -5.13% | -10.18% | 6.44% | 21.08% | 30.59% | Upgrade
|
Free Cash Flow Margin | 17.95% | 10.66% | 14.35% | 16.75% | -8.81% | 9.45% | Upgrade
|
EBITDA | 55.4 | 53.26 | 40.98 | 32.46 | 2.97 | -0.9 | Upgrade
|
EBITDA Margin | 16.40% | 16.23% | 13.96% | 13.33% | 1.49% | -1.90% | Upgrade
|
D&A For EBITDA | 47.4 | 46.89 | 58.04 | 45.29 | 29.28 | 3.73 | Upgrade
|
EBIT | 8 | 6.37 | -17.06 | -12.83 | -26.31 | -4.64 | Upgrade
|
EBIT Margin | 2.37% | 1.94% | -5.81% | -5.27% | -13.19% | -9.77% | Upgrade
|
Effective Tax Rate | - | - | - | - | 1.01% | 20.85% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.